Nasal fentanyl alone plus buccal midazolam: an open-label, randomised, controlled feasibility study in the dying

التفاصيل البيبلوغرافية
العنوان: Nasal fentanyl alone plus buccal midazolam: an open-label, randomised, controlled feasibility study in the dying
المؤلفون: Ralph K. Akyea, Anne Parkinson, Emma Husbands, Paul Perkins
المصدر: BMJ Supportive & Palliative Care. 10:300-303
بيانات النشر: BMJ, 2020.
سنة النشر: 2020
مصطلحات موضوعية: Male, medicine.medical_specialty, Midazolam, Population, Medicine (miscellaneous), Fentanyl, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, law, Oral administration, Medical–Surgical, medicine, Humans, 030212 general & internal medicine, education, Administration, Intranasal, Oncology(nursing), Terminal Care, education.field_of_study, Oncology (nursing), business.industry, Palliative Care, Administration, Buccal, General Medicine, Buccal administration, Patient Acceptance of Health Care, Medical–Surgical Nursing, Emergency medicine, Quality of Life, Feasibility Studies, Drug Therapy, Combination, Female, Observational study, business, 030217 neurology & neurosurgery, medicine.drug
الوصف: IntroductionMany patients want to stay at home to die. They invariably become unable to take oral medication during their terminal phase. Symptoms are usually controlled by subcutaneous medications. There have been no studies on nasal fentanyl (NF) or buccal midazolam (BM) to control symptoms in the dying.ObjectiveTo establish how best to conduct a definitive, randomised controlled trial (RCT) to determine whether NF and BM administered by families, for patients dying at home, lead to faster and better symptom control and fewer community nursing visits than standard breakthrough medication by healthcare professionals.MethodsThis open-label mixed-method feasibility RCT compared the efficacy of NF and BM by family members to standard breakthrough medication by nurses for the terminally ill in a specialist palliative care unit. Partway through the study, a third observational arm was introduced where BM alone was used. The primary outcomes were whether recruitment and randomisation were possible, assessment of withdrawal and drop-out, and whether the methods were acceptable and appropriate.ResultsAdministration of NF and BM was acceptable to patients and families. Both were well tolerated. We were unable to obtain quality of life data consistently but did get time period data for dose-controlled symptoms.ConclusionsStudy participation in a hospice population of the dying was acceptable. The results will help guide future community study planning.Trial registration numberNCT02009306.
وصف الملف: PDF
تدمد: 2045-4368
2045-435X
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462b72fd5e14e6fcd129cdfcffbe0434
https://doi.org/10.1136/bmjspcare-2019-002029
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....462b72fd5e14e6fcd129cdfcffbe0434
قاعدة البيانات: OpenAIRE